Sarepta Gene Therapy Setbacks - Search News

Order byBest matchMost fresh

News

Sarepta, gene therapy

BioPharma Dive · 12d

Sarepta to lay off about 500 employees after Duchenne gene therapy setbacks

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was essential to ensuring Sarepta's "long-term viability."

Continue reading

· 3d · on MSN

Sarepta fails to win EU backing for muscle disorder gene therapy

Sarepta's Setback Deepens With Another Gene Therapy Fatality

Fierce Pharma3d

Roche won't throw in the towel after DMD gene therapy Elevidys' rebuff in Europe

Despite a new setback for Elevidys in Europe, Roche—which markets Sarepta’s gene therapy outside the U.S.—remains committed ...

5don MSN

Sarepta's licensing partner Arrowhead expects near-term payments despite setbacks

Sarepta Therapeutics' licensing partner Arrowhead Pharmaceuticals said on Wednesday it expects to receive near-term milestone ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results